Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Return on Capital Employed (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Return on Capital Employed for 15 consecutive years, with 1.23% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed rose 242.0% year-over-year to 1.23%, compared with a TTM value of 1.23% through Sep 2025, up 242.0%, and an annual FY2024 reading of 1.0%, down 1.0% over the prior year.
  • Return on Capital Employed was 1.23% for Q3 2025 at Alaunos Therapeutics, up from 1.72% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.84% in Q1 2021 and bottomed at 4.46% in Q1 2024.
  • Average Return on Capital Employed over 5 years is 1.83%, with a median of 1.23% recorded in 2025.
  • The sharpest move saw Return on Capital Employed plummeted -356bps in 2024, then soared 267bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.88% in 2021, then rose by 5bps to 0.84% in 2022, then tumbled by -244bps to 2.88% in 2023, then surged by 32bps to 1.96% in 2024, then soared by 37bps to 1.23% in 2025.
  • Business Quant data shows Return on Capital Employed for TCRT at 1.23% in Q3 2025, 1.72% in Q2 2025, and 3.03% in Q1 2025.